News

Unituxin is administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin. Neuroblastoma is the most common extracranial solid cancer in childhood and the most common

Under the terms of the agreement, AVEO will receive an upfront payment of $15 million and will be eligible to receive reimbursement, clinical, sales and regulatory-based milestone payments

Said to be the first product approved through the partnership, Cefazolin injection is a cephalosporin antibacterial indicated for preoperative prophylaxis treatment. Galaxy is Baxter’s flexible container that makes

Following an initial period of exclusivity for the two target combinations, Novo Nordisk will also be at liberty to take the licenses forward on a non-exclusive basis. The

Under the agreement, New WuXi Life will acquire WuXi PharmaTech for cash consideration equal to $5.75 per ordinary share and $46 per American depositary share (ADS). Each ADS

As per the agreement, which comprises an initial cash license fee and a per-unit royalty of the greater of $50 or 20% of the gross purchase price paid

The open-label, multicenter, single-arm Phase II study BIRCH observed that atezolizumab shrank tumors in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed

In either the single or multiple ascending dose arms of the double-blind, randomized clinical trial, CAT-2054 was well-tolerated with no serious adverse events (AEs) observed. In the multiple

Plegridy is a new molecular entity, resulting from the application of pegylation technology and it offers a new combination of demonstrated efficacy, a favourable safety profile consistent with